This week was difficult for Denmark's stock market, Bloomberg writes.

On Monday criminal probe was started against the largest in the country bank Danske Bank A/S accused of laundering of $9 billion. Later Pandora A/S, the biggest producer of jewelry in the world, warned about revenue cut. Transport giant A.P. Moller Maersk A/S followed the suit.

On Wednesday pharmaceutical giants Novo Nordisk A/S and H. Lundbeck A/S issued their reports. Shares of Novo fell more than 5% due to concerns about weaker insulin market and price decline in the US. Shares of Lundbeck lost 11% after company announced that competition in generic drugs will hit sales.

The day ended with report of machinery producer for cement and minerals sector, FLSmidth A/S, which did not meet estimates in regards to EBIDTA.

Shares of biotechnical company Genmab A/S fell on Thursday despite on optimistic profit outlook. Transportation company Norden A/S reduced yearly results forecast due to weaker tanker spot market and observed its shares falling.

According to experts, shares of Denmark’s companies got too high valuations recently. This is why they fell after signs that they might not meet their financial goals. Even companies that reached estimates do not get enough reward from investors.

Index OMXC25 dropped 1,6% since its opening on Monday.